To directly dissect the role of each immune component in human tumor immunopathogenesis, we have studied the interaction between dendritic cells and T cells in the tumor environment of patients with ovarian carcinoma. We previously reported that functional plasmacytoid dendritic cells, but not functionally mature myeloid dendritic cells, accumulated in tumor microenvironments. We now show that tumor ascites macrophage-derived dendritic cells induced tumor-associated antigen-specific CD8 
Introduction
Human cancers are able to prime tumor-specific immunity. There exist tumor-specific T lymphocytes in blood, tumor tissues, and lymph nodes in cancer patients. Isolated tumor-associated antigen-specific T cells can kill autologous tumor cells. Functional tumor-associated antigen-specific T cell lines can be established from tumor T cells (1) (2) (3) (4) (5) . Furthermore, studies have shown increases in tumor-associated antigen-specific cytotoxic CD8 + T cells without evidence of clinical regression in some patients (2, 6, 7) . This suggests that tumor-associated antigenspecific T cells might be functionally inhibited in vivo. The underlying mechanisms were extensively reviewed (8) .
Dendritic cells play a critical role in establishing tumor immunity. However, because of the rarity of dendritic cells in vivo, primary dendritic cell studies are confined to in vitro differentiated myeloid dendritic cells. Published, detailed studies of functional human dendritic cells in tumor environment are rare (9) . Furthermore, another dendritic cell subset, plasmacytoid dendritic cells are technically more difficult to study. T cell activation pattern induced by plasmacytoid dendritic cells are largely determined in the allogeneic system. Little is known of the role of tumor environmental plasmacytoid dendritic cells in tumor immunity (9, 10) . These limitations may significantly underestimate the impact of the dendritic cell system in tumor pathology. We have studied malignant ascites of patients with ovarian carcinoma. Malignant ascites contains viable tumor and immune cells, and serves as a model for the tumor microenvironment (9-13). We identified a significant population of plasmacytoid dendritic cells in malignant ascites. In an allogeneic system, normal blood plasmacytoid dendritic cells (14, 15) and tumor plasmacytoid dendritic cells (9) induce interleukin (IL)-10 expressing suppressive T cells. In this report, we further studied the pathologic interaction between tumor ascites T cells and tumor ascites plasmacytoid dendritic cells, and its impact on tumor-associated antigen-specific T cell immunity.
Materials and Methods
Human subjects. We studied previously untreated patients with epithelial ovarian carcinomas, International Federation of Gynecology and Obstetrics stages I, II, III, and IV. Patients gave written, informed consent. Clinical specimens were collected at the Tulane University, New Orleans. The study was approved by local Institutional Review Boards.
Ascites, ascites cells, and tumor-draining lymph nodes. We collected and prepared single cells from ascites, blood, and lymph nodes as previously described (9, 16) . CD3, CD14, CD16, CD19, and CD56-expressing cells were depleted using paramagnetic beads (Miltenyi, Auburn, CA), and plasmacytoid dendritic cells were sorted with FACSAria gating on CD4
CD11c
À cells. Cell populations were z99% pure by flow cytometry analysis ( fluorescence-activated cell sorting, FACS). Tumor ascites T cells were obtained by depleting CD14, CD16, CD19, CD56, and CD123-expressing cells using microbeads (Miltenyi), and sorting CD45 + cells by flow cytometry. Cellular purity was z98% as determined by FACS staining with anti-human CD3 antibody. Antibodies for flow cytometry and depletion were purchased from BD PharMingen, San Jose, CA. Autologous ascites cells were used throughout this study.
Peripheral blood cells. Peripheral blood was collected aseptically from normal volunteers or patients by venipuncture or by cytophoresis, and mononuclear cells were then obtained by Ficoll-Hypaque density centrifugation. Blood plasmacytoid dendritic cells were obtained as described for tumor ascites plasmacytoid dendritic cells. Cells were z98% pure as determined by FACS.
In vitro tumor-associated antigen-specific T cell stimulation. Tumor myeloid dendritic cells were differentiated from tumor macrophages as previously described (17) . Tumor plasmacytoid dendritic cells were sorted from ascites as we previously described (9) . Dendritic cells were activated with CD40L (200 ng/mL) for 24 hours (17) , and loaded with three distinct HLA-A2-binding Her-2/neu peptides (13, 18) In vitro tumor-associated antigen-specific immunosuppression assay. After two rounds of stimulation with tumor-associated antigenplasmacytoid dendritic cells, ascites T cells (0.5-2 Â 10 5 /mL; on day 13) were added into tumor-associated antigen-myeloid dendritic cells (10 4 /mL) and primary ascites T cell (5 Â 10 5 /mL) coculture for 6 days. Tumor-associated antigen-specific T cell proliferation and cytokines were detected as we described (9, 13, 16) . In some cases, anti-human IL-10 receptor (250 ng/mL; 3F8, rat anti-human IgG 2a , PharMingen) and anti-human IgG (250 ng/mL; R35-95, rat anti-human IgG 2a , PharMingen) were added into the coculture.
Migration assay. After two rounds of stimulation with tumor-associated antigen-plasmacytoid dendritic cells, or tumor-associated antigen-myeloid dendritic cells, day 13 Tcells (2 Â 10 5 ) were initially incubated with 500 ng/mL mouse anti-human CCR7 monoclonal antibody (clone 150503, mouse IgG 2a , R & D) or control monoclonal antibody (clone G155-178, mouse IgG 2a , BD PharMingen) for 2 hours, and then subjected to in vitro migration assay as we have previously described (9) . Recombinant, human chemokines (MIP-3a and MIP-3h, 100 ng/mL each; R & D) were added to the lower chamber. The identity of migrating cells was confirmed by FACS for CD8 and CCR7.
T cell repetitive stimulation with tumor plasmacytoid dendritic cells and myeloid dendritic cells. Autologous tumor T cells were labeled with 10 Am 5,6-carboxyfluorescein diacetate succinimidyl ester (Molecular Probes, Eugene, OR) for 10 minutes in the dark at 37jC. 5,6-Carboxyfluorescein diacetate succinimidyl ester-labeled tumor T cells (5 Â 10 5 /mL) were divided into three groups. Group 1 received three rounds of identical stimulation with tumor-associated antigen-plasmacytoid dendritic cells. Group 2 received three rounds of identical stimulation with tumor-associated antigen-myeloid dendritic cells. Group 3 initially received one round of stimulation with tumor-associated antigen-plasmacytoid dendritic cells and followed two rounds of stimulation with tumor-associated antigen-myeloid dendritic cells. Tumor-associated antigen-specific T cell proliferation and cytokines were detected as we previously described (9, 13, 16) . Autologous tumor-associated antigen-dendritic cells (10 3 -10 4 /mL) were used. Real-time reverse transcriptase PCR. CCR7 + CD45RO + CD8 + T cells were sorted from blood, tumor ascites, and tumor-draining lymph nodes. cDNA was prepared from CCR7 + CD45RO + CD8 + T cells. Real-time reverse transcriptase-PCR was carried out for IL-10 (upstream 5V -atgcttcgagatctccgaga-3V , downstream 5V -aaatcgatgacagcgccgta-3V ), IFN-g (upstream 5V -gcagagccaaattgtctcct-3V , downstream 5V -atgctcttcgacctcgaaac-3V ) and housekeeping gene gyceraldehyde-3-phosphate dehydrogenase (GAPDH). Complementary DNA was normalized against, and expressed as fold differences relative to, GAPDH (19) as we have previously described (13) .
Statistical analysis. Differences in cell surface molecule expression were determined by m 2 test, and in other variables by unpaired t test, with P < 0.05 considered significant.
Results
Tumor plasmacytoid dendritic cells and myeloid dendritic cells induce distinct T cell activation. To determine the pathologic significance of tumor environmental plasmacytoid and myeloid dendritic cells on tumor-associated antigen-specific immunity, we used our previously described in vitro tumorassociated antigen-specific culture system (9, 13, 16) . Myeloid dendritic cells were differentiated in vitro from ascites macrophages of HLA-A2 + patients as described in ref. (17), and loaded with HLA-A2-specific Her-2/neu peptides (tumor-associated antigen-myeloid dendritic cells; refs. 13, 18) . Autologous CD40L-activated tumorassociated antigen-myeloid dendritic cells induced specific T cell activation as expected ( Fig. 1) .
To study the function of tumor plasmacytoid dendritic cells in the context of tumor-associated antigen-specific T cell immunity, we sorted tumor plasmacytoid dendritic cells from ascites (9, 20) . The functional identity of plasmacytoid dendritic cells were confirmed by their capacity to produce copious amounts of type I IFN after adenovirus activation (9) . Tumor plasmacytoid dendritic cells were loaded with HLA-A2-specific Her-2/neu peptides (tumor-associated antigen-plasmacytoid dendritic cell). Autologous CD40L-activated tumor-associated antigen-plasmacytoid dendritic cells induced a modest T cell proliferation. Tumor plasmacytoid dendritic cells were significantly less efficient in inducing T cell proliferation than myeloid dendritic cells (n = 4; *, P < 0.001 for all; + cells was also significantly higher in malignant ascites and tumor-draining lymph nodes than in peripheral blood (P < 0.01) in the same individual patients (Table 1) .
To determine whether original ascites CCR7 + CD8 + T cells affected the induction of IL-10 + CCR7 + CD45RO + CD8 + T cells by tumor plasmacytoid dendritic cells, we did the similar experiments by initially deleting CCR7 + ascites T cells with magnetic beads, and stimulated CCR7
À ascites T cells with tumor-associated antigenplasmacytoid dendritic cells. We detected similar levels of IL-10 (243 F 83 pg/mL versus 221 F 53 pg/mL) in the supernatant from CCR7 À ascites T cell and tumor-associated antigen-plasmacytoid dendritic cell coculture (P = 0.12, compared with no CCR7 depletion). The data suggest that original CCR7 + CD8 + T cells are not essential for tumor plasmacytoid dendritic cells to induce IL-10-expressing T cells.
Tumor plasmacytoid dendritic cell-induced IL-10 + CD8 + T cells migrate with MIP-3B. To further determine whether CCR7 is functional in tumor plasmacytoid dendritic cell-induced IL-10 + CD8 + T cells, we conducted a chemotaxis assay with MIP-3h (CCL19), the ligand for CCR7. We observed that a fraction of tumor plasmacytoid dendritic cell-activated T cells efficiently migrated with MIP-3h, but not with MIP-3a and medium (data not shown), and neutralizing mouse anti-human CCR7 monoclonal antibodies efficiently blocked this migration (n = 4; *, P < 0.001; Fig. 2B ). FACS analysis revealed that the migrated cells were uniquely CCR7 + CD8 + T cells (Fig. 2B) . Tumor myeloid dendritic cell-activated T cells poorly migrated in these conditions. CCR7 was solely expressed on IL-10 + CD8 + T cells (Fig. 2A) . Thus, tumor plasmacytoid dendritic cell-induced IL-10 + CD8 + T cells expressed functional CCR7, which would allow them to return to the tumordraining lymph nodes.
Tumor plasmacytoid dendritic cell-induced IL-10 + CCR7 + CD8 + T cells are suppressive. We next studied whether tumor plasmacytoid dendritic cell-induced IL-10 + CCR7 + CD8 + T cells are suppressive. To this end, autologous tumor ascites T cells were initially activated with tumor-associated antigenplasmacytoid dendritic cells as described (Fig. 1A) . Then, different concentrations of tumor plasmacytoid dendritic cell-activated T cells were added into autologous tumor-associated antigenmyeloid dendritic cell and T cell coculture system. As expected, myeloid dendritic cells induced strong tumor-associated antigenspecific T cell proliferation in the absence of plasmacytoid dendritic cell-activated T cells ( Fig. 3A and B) . Interestingly, tumor plasmacytoid dendritic cell-activated T cells significantly inhibited myeloid dendritic cell-mediated, Her2/neu-specific T cell proliferation in a dose-dependent manner (n = 4; *P < 0.05, **P < 0.01, compared with controls; Fig. 3A ). Tumor-associated antigenspecific T cell IFN-g production was also suppressed (n = 4; *P < 0.01; Fig. 3C ). Interestingly, mouse neutralizing anti-human IL-10 receptor antibody significantly recovered T cell functions ( Fig. 3B and C) . The data indicate that tumor plasmacytoid dendritic cell-induced CD8 + T cells are suppressive and that IL-10 is critical for this suppression.
Myeloid dendritic cell stimulation fails to recover tumor plasmacytoid dendritic cell-elicited poor T cell function. Myeloid dendritic cells have been used as immune-boosting vaccines to treat patients with cancers. It is unknown whether repetitive myeloid dendritic cell vaccination could override the T cell immunosuppressive function induced by tumor plasmacytoid dendritic cells. To test this possibility, autologous tumor ascites T cells were initially stimulated with tumor plasmacytoid dendritic cells followed by repetitive myeloid dendritic cell stimulation. As expected, repetitive myeloid dendritic cell stimulation (without plasmacytoid dendritic cells) induced strong tumor-associated antigen-specific T cell proliferation (n = 4; Fig. 3D ). Repetitive plasmacytoid dendritic cell stimulation (without myeloid dendritic cells) induced a modest tumorassociated antigen-specific T cell proliferation (n = 4; Fig. 3D ). Interestingly, after two rounds of myeloid dendritic cell stimulation, T cells prestimulated with tumor plasmacytoid dendritic cells exhibited strong T cell proliferation and cellular divisions, comparable to T cells that received three rounds of myeloid dendritic cell stimulation ( Fig. 3D and E) . However, after myeloid dendritic cell stimulation, the T cells previously stimulated with tumor plasmacytoid dendritic cells produced IL-10 (170 F 68 pg/mL) and expressed little IFN-g (0.12 F 0.05 ng/mL), which was largely observed in the first two cell divisions (5 F 2% IFN-g + T cells; Fig. 3E ). The IL-10-expressing cells were CD8 + T cells, similar to tumor plasmacytoid dendritic cell stimulation alone Fig. 2A) . Whereas T cells stimulated with myeloid dendritic cells (without plasmacytoid dendritic cells), expressed strong T cell IFN-g (total 55 F 7%), 40% of IFN-g expressing T cells were observed in the fourth cell division, indicating potent effector functions (Fig. 3E) . Therefore, repetitive myeloid dendritic cell stimulation is unable to override the T cell-defective function initially induced by tumor plasmacytoid dendritic cells.
Primary T cells from peripheral blood, primary tumor ascites, and primary tumor-draining lymph node in patients with ovarian cancer, whereas normal blood CCR7 + CD45RO + CD8 + T cells expressed a negligible level of IL-10 mRNA (*, P < 0.001, compared with normal blood; Fig. 4A) . Furthermore, the level of IL-10 mRNA was at least 2-fold higher in CCR7 + CD45RO + CD8 + T cells from tumor ascites than that from blood and lymph nodes (Fig. 4A) . All the CCR7 + CD45RO + CD8 + T cells expressed comparable, but low levels of IFN-g, whereas activated normal T cells expressed high IFN-g (Fig. 4B) (Fig. 2) .
Discussion
Published, detailed functional studies of dendritic cells and T cells in human tumor environment are scarce. Here, we studied the interaction between plasmacytoid dendritic cells and T cells in the tumor microenvironment in ovarian carcinomas. We show that tumor plasmacytoid dendritic cells induce regulatory CD8 + T cells.
There are several proposals to explain why the immune system fails to control tumor progression, including deletions or mutations affecting the genes encoding proteins in the MHC class I pathway, or the antigen itself (21), altered TCR signal transduction or expression (22) , triggering of Fas receptor on CD8 + T cells by Fas ligand expressed by tumor cells (23) , and producing inhibitory cytokines such as TGF-h and IL-10. We recently showed that tumor environmental CD4 + CD25 + FOXP3 + T cells contribute to tumor-associated antigen-specific immunosuppression (13) . Apart from these possibilities, the dendritic cell system is thought to contribute to tumor immunopathogenesis. Tumorderived cytokines, such as IL-6, IL-10, M-CSF, and vascular endothelial growth factor inhibit dendritic cell-differentiation, maturation, and function (8, 16, 24) . Immature dendritic cells are found in tumor tissues (25) , which might induce IL-10-expressing CD4 + regulatory T cells (26, 27) . This report, in conjunction with our previous work (9), show for the first time that human tumors mediate plasmacytoid dendritic cell tumor trafficking and enable plasmacytoid dendritic cells to induce CD8 + regulatory T cells.
Normal blood plasmacytoid dendritic cells are shown to induce immunosuppressive T cells in an allogeneic T cell reaction (14, 15) . We previously showed that tumor environmental plasmacytoid dendritic cells promoted tumor vascularization (10) , and induced IL-10-expressing T cells (9) . We now show that tumor plasmacytoid dendritic cells induce CD8 regulatory T cells in the context of tumor-specific immunity. Although the mechanisms whereby tumor plasmacytoid dendritic cells induce CD8 regulatory T cells remain to be defined, we have identified four characteristics for these plasmacytoid dendritic cell-induced IL- /mL). Different concentrations of these tumor-associated antigen-plasmacytoid dendritic cell-stimulated T cells were added into autologous tumor-associated antigen-myeloid dendritic cells (10 4 /mL) and primary T cell (5 Â 10 5 /mL) coculture, and were further cultured for 6 days. T cell proliferation was detected by thymidine incorporation. Ratio, plasmacytoid dendritic cell-activated T cells/primary tumor ascites T cells (n = 4, *, P < 0.05; **, P < 0.01, compared with the group without plasmacytoid dendritic cell-activated T cells). B and C, anti-human IL-10 receptor was added into the coculture as described above. On day 6, T cell proliferation (B) and IFN-g (C ) production were detected as described. The ratio between primary tumor ascites T cells and tumor-associated antigen-plasmacytoid dendritic cell-stimulated T cells was 1:1 (n = 4; *, P < 0.01, compared with the group with anti-human IL-10R). D and E, 5,6-carboxyfluorescein diacetate succinimidyl ester-labeled autologous tumor T cells (5 Â 10 5 /mL) were divided into three groups. Group 1 received only tumor-associated antigen-myeloid dendritic cell (10 3 -10 4 /mL) stimulation. Group 2 initially received tumor-associated antigen-plasmacytoid dendritic cell (10 4 /mL) stimulation, and followed with tumor-associated antigen-myeloid dendritic cell (10 3 -10 4 /mL) stimulation. Group 3 received only tumor-associated antigen-plasmacytoid dendritic cell (10 3 -10 4 /mL) stimulation. D, T cell proliferation was determined by thymidine incorporation. E, T cell IFN-g expression and cell divisions were shown when autologous tumor T cells (5 Â 10 5 /mL) were stimulated with 10 4 /mL tumor-associated antigen-dendritic cells. One of four independent experiments is shown. À alloantigen-specific T suppressor cells were observed in human heart transplant recipients (32) . Human CD8 + CD25 + thymocytes are reported to mediate suppressive effects through CTLA4 and TGF-h in normal donors (33) . Murine CD8 + regulatory T cells with central memory phenotype were also reported to be a novel CD8 + regulatory T cell population (34) . Our data suggest that tumor plasmacytoid dendritic cells would contribute to CD8 + regulatory T cell induction. CD8 + regulatory T cells may inhibit tumor-associated antigen-specific effector T cell immunity at the functional sites (tumor sites), and further home to lymph node and suppress tumor-associated antigen-specific naïve T cell central priming at the priming sites.
No immunogeneic ( functionally mature) myeloid dendritic cells are detected in malignant ascites, suggesting that their absence is immunopathologically relevant, and means to introduce them into the tumor might be therapeutic. However, if myeloid dendritic cells cannot recover T cell effector functions after plasmacytoid dendritic cell induction, as shown in this study, blocking plasmacytoid dendritic cell tumor trafficking or functions may be essential prior to boosting tumor immunity by myeloid dendritic cells. Our data, in conjunction with the work from other groups (35) (36) (37) (38) (39) (40) (41) (42) , may at least partially explain why tumor-bearing hosts often have established weak tumor immunity, not sufficient to control disease progress, and why only moderate clinical benefits are observed in myeloid dendritic cellbased immunotherapy.
In summary, our study indicates that tumors manipulate tumor environmental dendritic cell subset distribution and functions to subvert tumor immunity (8) . Multiple cellular and molecular layers of the suppressive network have been imposed in the tumor microenvironment in patients with cancers (8, (35) (36) (37) (38) (39) (40) (41) (42) . We suggest that a combination therapy with subverting immunosuppressive mechanisms, including blocking plasmacytoid dendritic cell tumor trafficking or function, is a promising, yet little-studied strategy for treating human cancers. + CD8 + T cells from blood, ascites, and tumor-draining lymph nodes. Activated T cells, normal blood T cells were stimulated with anti-CD3 (2.5 Ag/mL) and anti-CD28 (5 Ag/mL) for 48 hours (positive control). C, primary tumor CCR7 + CD45RO + CD8 + T cells are suppressive. Primary CCR7 + CD45RO + CD8 + T cells were sorted from normal blood and tumor ascites, and cocultured with allogeneic T cells in different ratios in the presence of anti-CD3. T cell proliferation was detected by thymidine incorporation. One of five experiments with five individual donors is shown (P < 0.05 for all, compared with blood).
